135 related articles for article (PubMed ID: 36218843)
1. Decomposition of Expenditures for Insulins Across the Distribution Chain-Insights Into Rising Prices?
Good CB; Hernandez I
JAMA Health Forum; 2021 Nov; 2(11):e212258. PubMed ID: 36218843
[No Abstract] [Full Text] [Related]
2. Why Are Diabetes Medications So Expensive and What Can Be Done to Control Their Cost?
McEwen LN; Casagrande SS; Kuo S; Herman WH
Curr Diab Rep; 2017 Sep; 17(9):71. PubMed ID: 28741264
[TBL] [Abstract][Full Text] [Related]
3. Growth of diabetes drug expenditure decomposed-A nationwide analysis.
Soppi A; Heino P; Kurko T; Maljanen T; Saastamoinen L; Aaltonen K
Health Policy; 2018 Dec; 122(12):1326-1332. PubMed ID: 30297302
[TBL] [Abstract][Full Text] [Related]
4. Higher insulin expenditures associated with utilization of free medication samples.
Brown JD
Res Social Adm Pharm; 2020 Sep; 16(9):1302-1305. PubMed ID: 31027965
[TBL] [Abstract][Full Text] [Related]
5. Expenditures and Prices of Antihyperglycemic Medications in the United States: 2002-2013.
Hua X; Carvalho N; Tew M; Huang ES; Herman WH; Clarke P
JAMA; 2016 Apr; 315(13):1400-2. PubMed ID: 27046369
[No Abstract] [Full Text] [Related]
6. Assessing-and Extending-California's Insulin Manufacturing Initiative.
Sherkow JS; Adashi EY; Cohen IG
JAMA; 2023 Feb; 329(7):533-534. PubMed ID: 36656599
[TBL] [Abstract][Full Text] [Related]
7. The impotence of price controls: failed attempts to constrain pharmaceutical expenditures in Greece.
Lambrelli D; O'Donnell O
Health Policy; 2011 Jul; 101(2):162-71. PubMed ID: 20884073
[TBL] [Abstract][Full Text] [Related]
8. Projecting future drug expenditures--2007.
Hoffman JM; Shah ND; Vermeulen LC; Schumock GT; Grim P; Hunkler RJ; Hontz KM
Am J Health Syst Pharm; 2007 Feb; 64(3):298-314. PubMed ID: 17244880
[TBL] [Abstract][Full Text] [Related]
9. Pharmacy and neighborhood-level variation in cash price of diabetes medications in the United States.
Warraich HJ; Siddiqi HK; Li DG; van Meijgaard J; Vaduganathan M
PLoS One; 2023; 18(12):e0294164. PubMed ID: 38060500
[TBL] [Abstract][Full Text] [Related]
10. Public financing of human insulins in Brazil: 2009-2017.
Dias LLDS; Santos MABD; Osorio-de-Castro CGS
Rev Bras Epidemiol; 2020; 23():e200075. PubMed ID: 32638853
[TBL] [Abstract][Full Text] [Related]
11. Addressing Insulin Access and Affordability: An Endocrine Society Position Statement.
Endocrine Society
J Clin Endocrinol Metab; 2021 Mar; 106(4):935-941. PubMed ID: 33433590
[TBL] [Abstract][Full Text] [Related]
12. Biosimilar Insulins and Their Impact on Prices and Utilization of Insulins in Bulgaria.
Tachkov K; Mitkova Z; Milushewa P; Petrova G
Healthcare (Basel); 2021 Jun; 9(6):. PubMed ID: 34207707
[TBL] [Abstract][Full Text] [Related]
13. Pharmaceutical policies: effects of reference pricing, other pricing, and purchasing policies.
Acosta A; Ciapponi A; Aaserud M; Vietto V; Austvoll-Dahlgren A; Kösters JP; Vacca C; Machado M; Diaz Ayala DH; Oxman AD
Cochrane Database Syst Rev; 2014 Oct; 2014(10):CD005979. PubMed ID: 25318966
[TBL] [Abstract][Full Text] [Related]
14. Trends in Medicaid Reimbursements for Insulin From 1991 Through 2014.
Luo J; Avorn J; Kesselheim AS
JAMA Intern Med; 2015 Oct; 175(10):1681-6. PubMed ID: 26301721
[TBL] [Abstract][Full Text] [Related]
15. When High Prices Mean Needless Death.
Rosenthal E
JAMA Intern Med; 2019 Jan; 179(1):114-115. PubMed ID: 30508014
[No Abstract] [Full Text] [Related]
16. Generic Price Regulation and Drug Expenditures: Evidence From Canada.
Li Y
Value Health; 2023 Jun; 26(6):833-840. PubMed ID: 36706953
[TBL] [Abstract][Full Text] [Related]
17. Managing the Rising Costs and High Drug Expenditures in Critical Care Pharmacy Practice.
Flannery AH; Pandya K; Laine ME; Almeter PJ; Flynn JD
Pharmacotherapy; 2017 Jan; 37(1):54-64. PubMed ID: 27995636
[TBL] [Abstract][Full Text] [Related]
18. [Costs of antihyperglycemic drugs and consumables and treatment satisfaction in patients with type 2 diabetes. Results of the health care research study LIVE-DE (long-acting insulin glargine compared with NPH insulin in Germany)].
Hauner H; Kohlmann T; Landgraf W; Holle R; Pirk O; Scholten T
Dtsch Med Wochenschr; 2009 Jun; 134(23):1207-13. PubMed ID: 19472091
[TBL] [Abstract][Full Text] [Related]
19. The impact of biosimilar insulins on the diabetes landscape.
White J; Wagner A; Patel H
J Manag Care Spec Pharm; 2022 Jan; 28(1):91-98. PubMed ID: 34726499
[TBL] [Abstract][Full Text] [Related]
20. [Des-phe-insulin-containing intermediary insulin compared with usual commercial preparations (author's transl)].
Sachse G; Mäser E; Schäfer D; Federlin K
Dtsch Med Wochenschr; 1982 Mar; 107(9):332-5. PubMed ID: 7037351
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
